Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.
Africa
COVID-19
HIV-1
SARS
SARS-CoV-2
Thailand
coronavirus
coronavirus disease
respiratory infections
serosurvey
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
pubmed:
12
10
2022
medline:
28
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, from 2,250 persons in 4 countries in Africa (Kenya, Nigeria, Tanzania, and Uganda) and in Thailand, including persons living with HIV-1. We detected IgG responses to SARS-CoV-2 spike (S) subunit 2 protein in 1.8% of participants. Profiling against 23 coronavirus antigens revealed that responses to S, subunit 2, or subunit 1 proteins were significantly more frequent than responses to the receptor-binding domain, S-Trimer, or nucleocapsid proteins (p<0.0001). We observed similar responses in persons with or without HIV-1. Among all coronavirus antigens tested, SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syndrome coronavirus antibody responses were much higher in participants from Africa than in participants from Thailand (p<0.01). We noted less pronounced differences for endemic coronaviruses. Serosurveys could affect vaccine and monoclonal antibody distribution across global populations.
Identifiants
pubmed: 36220131
doi: 10.3201/eid2811.221041
pmc: PMC9622245
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Viral
0
Immunoglobulin G
0
Nucleocapsid Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2214-2225Subventions
Organisme : NIAID NIH HHS
ID : AAI20052001
Pays : United States
Références
J Immunol Methods. 2020 Dec;487:112874
pubmed: 33022219
Virus Evol. 2021 Feb 05;7(1):veab007
pubmed: 33754082
Nat Commun. 2021 Nov 18;12(1):6703
pubmed: 34795285
NPJ Vaccines. 2022 Feb 28;7(1):28
pubmed: 35228535
EBioMedicine. 2021 Dec;74:103700
pubmed: 34861490
J Clin Microbiol. 2021 Jun 18;59(7):e0051421
pubmed: 33853839
Viruses. 2022 Jan 09;14(1):
pubmed: 35062318
Cell. 2021 Apr 1;184(7):1858-1864.e10
pubmed: 33631096
mBio. 2020 Sep 25;11(5):
pubmed: 32978311
Trop Med Int Health. 2021 Jun;26(6):621-631
pubmed: 33666297
Emerg Infect Dis. 2022 Feb;28(2):440-444
pubmed: 35076009
AIDS. 2021 Sep 1;35(11):1872-1874
pubmed: 33993131
Emerg Infect Dis. 2021 Jan;27(1):
pubmed: 33261717
Lancet HIV. 2022 May;9(5):e323-e331
pubmed: 35338835
Sci Immunol. 2021 Oct 15;6(64):eabj2901
pubmed: 34652962
Proc Natl Acad Sci U S A. 2021 Sep 21;118(38):
pubmed: 34470866
J Immunol Methods. 2021 Oct;497:113104
pubmed: 34303688
MMWR Morb Mortal Wkly Rep. 2022 Mar 11;71(10):375-377
pubmed: 35271558
Clin Immunol. 2021 Aug;229:108782
pubmed: 34118402
Front Immunol. 2022 Apr 27;13:856033
pubmed: 35585976
J Immunol Methods. 2011 Mar 7;366(1-2):8-19
pubmed: 21192942
Microbiol Spectr. 2021 Sep 3;9(1):e0013421
pubmed: 34319133
Science. 2020 Nov 27;370(6520):
pubmed: 32994364
Microbiol Resour Announc. 2019 Jul 11;8(28):
pubmed: 31296683
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855
pubmed: 34438069
Cell Host Microbe. 2022 Sep 14;30(9):1269-1278.e4
pubmed: 35932763
EClinicalMedicine. 2022 Jan;43:101226
pubmed: 34901799
Int J Infect Dis. 2020 Dec;101:191-193
pubmed: 33002616
Nature. 2022 Mar;603(7903):913-918
pubmed: 35114688
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Int J Infect Dis. 2021 Jan;102:118-122
pubmed: 33075535
Int J Infect Dis. 2021 Jan;102:577-583
pubmed: 33176202
Nat Commun. 2021 May 19;12(1):2938
pubmed: 34011939
PLoS Pathog. 2022 Sep 22;18(9):e1010828
pubmed: 36136995